An international study has found out about a miracle drug showing reduced life-threatening critical organ bleeding in patients undergoing cardiac surgery.
It has been revealed that this blood-clotting medicine reduced blood loss without increasing major vascular complications.
This study called Perioperative Ischemic Evaluation (POISE-3) was conducted at multiple centers around the world. Shifa International Hospital served as a National Coordinating Center in Pakistan under the supervision of Shifa Clinical Research Center and Principal Investigator Prof. Dr. Muhammad Amir who is a consultant in General Surgery and Principal of Shifa College of Medicine.
The most important thing in the research was, the medicine Tranexamic acid (TXA) was given to individuals who were at higher risk of bleeding.
The findings were presented by the Principal Investigator for POISE-3 at Mcmaster University’s Population Health Research Institute and Hamilton Health Sciences (HHS) Dr. P.J. Devereaux at the American College of Cardiology’s 2022 conference.
He further said, “Our research shows that tranexamic acid can help prevent this major bleeding and the need for blood transfusions”.
The co-author of the study Dr. Amir Consultant of General Surgery said that “Tranexamic acid revealed a consistent reduction in the risk of bleeding based on different definitions, and it reduced the chance of receiving 1 or 2 to 4 transfusions. Given that 300 million procedures are performed each year around the world,” Dr. Amir noted, “tranexamic acid has the potential for significant public health and clinical advantages”.
Further expectations of such miraculous results have increased after this revelation.